Skip to main content

Table 1 OLE baseline characteristics of patients with PET scan at OLE week 52

From: Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis

Characteristic MR-DBP (n = 27) MR-DBA (n = 21) SR (n = 19)
Age at start of OLE, median (IQR), years 74 (69–77) 65 (59–79) 72 (70–78)
Female, n (%) 12 (44) 11 (52) 11 (58)
White, n (%) 27 (100) 20 (95) 19 (100)
APOEε4 genotype, n (%)
 0 9 (33) 10 (48) 2 (11)
 1 13 (48) 4 (19) 14 (74)
 2 5 (19) 7 (33) 3 (16)
MMSE score at OLE baseline, mean (SD) 21.6 (4.5) 19.3 (5.0) 18.8 (4.8)
Centiloid at OLE baseline, mean (SD) 91.1 (46.8) 79.6 (51.6) 49.6 (52.8)
Duration on high dose, median (IQR), weeksa 35 (33–37) 42 (40–45) 25 (21–33)
Duration between baseline and week 52 PET scan, median (IQR), weeks 68 (60–82) 73 (64–88) 55 (54–58)
Patients with baseline PET scan below amyloid-β threshold, n (%) 0 3 (14) 7 (37)
  1. aHigh dose: ≥ 6 doses (6 months) of 900 to 1200 mg gantenerumab